Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2026
Osimertinib plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD.
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03944772 (A Biomarker-directed Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy.), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Biomarker-directed Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
purposeORCHARD (NCT03944772) was a phase II, open-label study evaluating resistance mechanisms and postprogression therapies in patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC) with progressive disease (PD) on first-line osimertinib. We report final data from the osimertinib plus gefitinib module in patients with EGFR C797X, a known resistance mechanism to osimertinib. PATIENTS AND
methodsPatients received once-daily osimertinib 80 mg plus gefitinib 250 mg until PD, unacceptable toxicity, or another discontinuation criterion. The primary endpoint was objective response rate (ORR) by investigator per Response Evaluation Criteria in Solid Tumors 1.1.
resultsThirty-one patients were treated and evaluable for response/safety (data cutoff: May 10, 2024). Eight patients had a partial response, for a confirmed ORR of 26% [80% confidence interval (CI), 16-39]; the median duration of response was 4.2 months (95% CI, 2.8-5.5). Thirty patients (97%) experienced a progression-free survival (PFS) event, and 19 patients (61%) died. Median PFS was 5.1 months (95% CI, 3.9-6.8), and median overall survival was 19 months (95% CI, 14.6-25). Eleven patients (35%) had grade ≥3 adverse events. Safety was consistent with the known adverse event profiles of the individual drugs, with no new safety signals. Several resistance mechanisms (EGFR T790M, BRAF, and PIK3CA mutations) were identified following PD on osimertinib-gefitinib.
conclusionsOsimertinib-gefitinib demonstrated modest clinical benefit in patients with EGFR-mutated advanced NSCLC harboring an EGFR C797X mutation identified following PD on first-line osimertinib. The risk-benefit profile indicates that further evaluation of this regimen is not warranted in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.